Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-modified immune cell therapy. The company was founded in 2017 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does Pell Bio-Med Technology Co., Ltd. (6949) operate in?
Pell Bio-Med Technology Co., Ltd. belongs to the Other sector and operates in the Biotechnology industry.
What is Pell Bio-Med Technology Co., Ltd. (6949) current stock price?
As of the latest data, Pell Bio-Med Technology Co., Ltd. stock price is NT$1,020.00, with a previous close of NT$1,010.00. Pell Bio-Med Technology Co., Ltd. gained NT$10.00 in the last trading session, representing a 0.99% increase.
What is Pell Bio-Med Technology Co., Ltd. (6949) current market capitalization?
Pell Bio-Med Technology Co., Ltd. market cap is approximately 66.85 billion.
What is Pell Bio-Med Technology Co., Ltd. (6949) Earnings Per Share (EPS)?
The trailing EPS is -NT$7.07.
What is Pell Bio-Med Technology Co., Ltd. (6949) EBITDA?
Pell Bio-Med Technology Co., Ltd. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -69.84 million.
Does Pell Bio-Med Technology Co., Ltd. (6949) pay dividends?
No. Pell Bio-Med Technology Co., Ltd. does not pay a dividend.
What is Pell Bio-Med Technology Co., Ltd. (6949) beta (volatility) score?
Pell Bio-Med Technology Co., Ltd. has a beta of 1.039, meaning its volatility is roughly in line with the market.
